Table 1 Patients’ demographic, clinical characteristics, management, and outcomes
From: Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: a case series
Patient | Sex/age (years) | Comorbidities/indication of CytoSorb | Clinical management | Outcomes |
|---|---|---|---|---|
1 | F/66 | COVID pneumonia Guillain–Barre syndrome Hypertension Diabetes/ Septic with MODS | Hydroxychloroquine Azithromycin Tocilizumab Plasma therapy Other antibiotics Dexamethasone | Discharged |
2 | M/55 | Hypertension Respiratory failure type-1/ Others | Hydroxychloroquine Azithromycin Tocilizumab Plasma therapy Dexamethasone | Discharged |
3 | M/42 | Hypertension Diabetes/ Septic with shock | Dexamethasone Remdesivir Tocilizumab Plasma therapy | Discharged |